Baxalta Ventures is the corporate venture capital arm of Baxalta with over $200 million under management, and is a core facet of Baxalta’s R&D strategy.
Our investment approach is primarily focused on accelerating development of cutting-edge innovative biotechnologies that address unmet patient needs in hematology, immunology and oncology.
Baxalta’s commitment to strive for excellence on behalf of patients, caregivers and healthcare providers is at the center of every investment we make.
- Baxalta Ventures is focused on fostering relationships. We believe that long-term success of our investments is best achieved by cultivating strong ties with entrepreneurs, fellow investors and industry experts.
- Through strong industry networks, active board representation, and leveraging Baxalta’s product development and commercialization expertise, we aim to maximize value creation in our portfolio companies.
- We are stage and series agnostic and can lead financing rounds or join established investment syndicates with an initial investment of about $5 million, while reserving capital for follow-on rounds.
Areas of Interest
We align our focus with Baxalta’s core businesses, directing our investment interests toward novel therapeutics, select diagnostics, IT solutions and leading-edge technology platforms that address disease management in these key therapeutic areas: